Sonnet Biotherapeutics receives shareholder approval for business merger with Hyperliquid Strategies Inc.
ChainCatcher News, according to market sources, Nasdaq-listed biotechnology company Sonnet Biotherapeutics has received shareholder approval and plans to merge its business with Hyperliquid Strategies Inc.
Previously, it was reported that Hyperliquid Strategies submitted an S-1 filing, aiming to raise up to 1 billion USD, which may be used to purchase HYPE tokens.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Uniswap partners with European financial app Revolut
"Big Short" Michael Burry: Bitcoin is the "tulip bulb" of our era and has no value
Nvidia CFO: No Final Agreement Reached with OpenAI Yet
